4.6 Review

Drug-induced Osteoporosis: Mechanisms and Clinical Implications

期刊

AMERICAN JOURNAL OF MEDICINE
卷 123, 期 10, 页码 877-884

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2010.02.028

关键词

Drugs; Fractures; Osteoporosis; Secondary osteoporosis

资金

  1. MIUR
  2. Centro di Ricerca sull'Osteoporosi-University of Brescia/EULO
  3. Eli Lilly
  4. GlaxoSmithKline
  5. Novartis
  6. Amgen
  7. Abiogen
  8. Merck
  9. Stroder

向作者/读者索取更多资源

Drug-induced osteoporosis is common and has a significant impact on the prognosis of patients suffering from chronic debilitating diseases. Glucocorticoids are the drugs causing osteoporotic fractures most frequently, but osteoporosis with fractures is observed also in women treated with aromatase inhibitors for breast cancer, in men receiving anti-androgen therapy for prostate cancer, in postmenopausal women treated with high doses of thyroxine, and in men and women treated with thiazolinediones for type 2 diabetes mellitus. Bone loss with fractures also occurs in patients treated with drugs targeting the immune system, such as calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin reuptake, anticonvulsants, loop diuretics, heparin, oral anticoagulants, and proton pump inhibitors. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 877-884

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据